Relmada Therapeutics, Inc. (RLMD)
Automate Your Wheel Strategy on RLMD
With Tiblio's Option Bot, you can configure your own wheel strategy including RLMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RLMD
- Rev/Share 0.0
- Book/Share 0.738
- PB 0.7266
- Debt/Equity 0.0
- CurrentRatio 5.2868
- ROIC -2.6486
- MktCap 17797336.0
- FreeCF/Share -1.8674
- PFCF -0.3134
- PE -0.2154
- Debt/Assets 0.0
- DivYield 0
- ROE -1.8126
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RLMD | Mizuho | Outperform | Neutral | $23 | $1 | Dec. 5, 2024 |
| Upgrade | RLMD | Jefferies | Hold | Buy | $3.5 | $13 | Sept. 17, 2024 |
News
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.
Read More
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation*
Read More
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024.
Read More
About Relmada Therapeutics, Inc. (RLMD)
- IPO Date 2014-06-20
- Website https://www.relmada.com
- Industry Biotechnology
- CEO Sergio Traversa
- Employees 17